All In Biotech

Drug Trial Radar · NCT04551300

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

A Phase 2 Study to Evaluate the Safety and Efficacy of Escalated and Fixed Doses of VS-505(AP301) in Comparison With Sevelamer Carbonate to Treat Hyperphosphatemia in Chronic Kidney Disease Patients Receiving Hemodialysis

Last checked: Nov 19, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Oct 13, 2020

Primary completion

Jun 30, 2022

Study completion Oct 15, 2022

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic kidney disease subjects receiving maintenance hemodialysis.

Conditions

  • Hyperphosphatemia

Interventions

  • VS-505Drug

    4 dosages of experimental drug

  • Sevelamer CarbonateDrug

    Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum phosphorus change from baseline to end of treatmentTime frame: 6 weeks

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital of Xingtai Medical College

    Xingtai, Hebei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The Second People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • Jilin Province People's Hospital

    Changchun, Jilin, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Dalina Municipal Central Hospital

    Dalian, Liaoning, China

  • The First Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong Universiity School of Medcine

    Shanghai, Shanghai Municipality, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.